NEW YORK, April 3, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE),
Nordion Inc. (NYSE: NDZ), Intuitive Surgical, Inc. (NASDAQ: ISRG),
and Novartis AG (NYSE: NVS). Private wealth members receive these
notes ahead of publication. To reserve complementary membership,
limited openings are available at:
http://www.AnalystsReview.com/register
--
Gilead Sciences Inc. Analyst Notes
On March 28, 2014, Gilead Sciences
Inc. (Gilead) announced a settlement method for its conversion
obligations related to any 1.00% Senior Convertible Notes due 2014
(Notes) submitted for conversion on or after February 1, 2014 entirely in cash. In accordance
with the foregoing, Gilead informed Wells Fargo Bank, National
Association, the Trustee for the Notes, that it had designated a
"Cash Percentage" (as defined in the indenture governing the Notes
(Indenture) of 100% to apply to the "Daily Share Amount" for every
"Trading Day" during the relevant "Conversion Reference Period"
(each as defined in the Indenture) applicable to the Notes. The
full analyst notes on Gilead Sciences Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04032014/GILD/report.pdf
--
Pfizer Inc. Analyst Notes
On March 28, 2014, Pfizer Inc.
(Pfizer) reported that US Food and Drug Administration (FDA) has
approved over-the-counter Nexium® 24HR (esomeprazole 20mg)
marking a key step towards providing broader access to a
brand, both, doctors and patients have trusted for years for people
suffering from frequent heartburn. The Company stated that it has
acquired exclusive global rights from AstraZeneca to market
non-prescription Nexium® in 2012. Commenting on the drug approval,
Paul Sturman, President, Pfizer
Consumer Healthcare, said, "Switching medicines, whenever
appropriate, from prescription to non-prescription status improves
access, empowers consumers to care for their own health and is an
important strategy for Pfizer. The FDA approval of
Nexium® 24HR is a significant milestone in executing against
our plan." The full analyst notes on Pfizer Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04032014/PFE/report.pdf
--
Nordion Inc. Analyst Notes
On March 31, 2014, shares of
Nordion Inc. (Nordion) skyrocketed 10.66% to end the trading
session at $11.52 on record high
volumes; a day after Nordion signed an agreement with Sterigenics,
in which the latter has agreed to acquire the former for
$11.75 per share in cash. On
March 28, 2014, Nordion announced
that it has entered into a definitive agreement with Sterigenics, a
global leader in sterilization services and a portfolio company of
GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA, to be acquired in a
transaction valued at nearly $727
million. After the acquisition, Nordion will operate as a
standalone company within Sterigenics and will continue to operate
under the Nordion name. The acquisition will be funded using a
combination of new debt facilities and equity financing, both of
which are fully committed, Sterigenics' cash on hand, and a portion
of Nordion's cash on hand. The transaction has been unanimously
approved by the Board of Directors of Nordion. The full analyst
notes on Nordion Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04032014/NDZ/report.pdf
--
Intuitive Surgical, Inc. Analyst Notes
On March 31, 2014, shares of
Intuitive Surgical, Inc.'s (Intuitive Surgical), a global leader in
robotic-assisted, minimally invasive surgery, surged 0.69%, closing
the trading session at $437.99.
During the session, the Company's shares opened at $434.98 and oscillated in the range of
$433.00 - $442.00. A total of 0.52
million shares were traded during the day, significantly higher
than its 30-day average trading volume of 0.37 million shares. Over
the previous three trading sessions, the shares of the Company
increased 3.14%, as compared to the NASDAQ Composite which moved
0.61% higher during the same period. The full analyst notes on
Intuitive Surgical, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04032014/ISRG/report.pdf
--
Novartis AG Analyst Notes
On March 31, 2014, Novartis AG (Novartis) reported that the Data
Monitoring Committee (DMC) unanimously recommended early closure of
the PARADIGM-HF study, a randomized, double-blind, Phase III
outcome study evaluating the efficacy and safety profile of LCZ696
versus enalapril (a widely used ACE inhibitor) in 8,436 patients
with heart failure with reduced ejection fraction. The study
indicated that patients with chronic heart failure with reduced
ejection fraction (HF-REF) who received LCZ696 lived longer without
being hospitalized for heart failure than those who received
standard care with ACE-inhibitor enalapril. However, based on the
compelling efficacy and primary endpoint having been met, the trial
will now close early. The Company informed that the results of
PARADIGM-HF will be submitted to a major medical conference for
presentation and it will also initiate discussions with global
health authorities regarding approval for marketing. The full
analyst notes on Novartis AG are available to download free of
charge at:
http://www.AnalystsReview.com/04032014/NVS/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review